Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Also Organics Celebrates Holiday Season with Special Discount on Best-Selling CBD Starter Pack


Also Organics offers a wide range of products including tinctures, gummies, gel caps, balms, salves, lotions and more. The Also Organics team believes there’s always more – to see, experience, and discover.

Also Organics CBD Starter Bundle is a customer favorite and is a great way to experience an array of products for alternative wellness.

“The holidays can be stressful, but natural alternatives and deep promo codes can help. Also Organics CBD products can help create a sense of calmness and well-being,” said Chewy Smith, founder of Also Organics.

Also Organics, maker of alternative personal wellness products, is celebrating the holidays with a seasonal promotion for its popular and already-discounted CBD Starter Pack. From now until December 25, 2020, gift givers or those seeking organic and holistic alternatives to help relieve effects of anxiety and calm uneasy nerves during the holiday season and beyond can save an additional 25 percent off the purchase price of the brand’s favorite CBD Starter Pack by using promo code HOLIDAY25. Orders placed by Wednesday, December 16, are guaranteed to arrive before Christmas.

“The holidays are often a stressful time for many, and with this year’s happenings bringing extra feelings of uncertainty and anxiety, our team wants to make natural options readily available for those seeking relief,” said Matthew ‘Chewy’ Smith, founder of Also Organics. “Whether using alternative products yourself or purchasing as a gift for loved ones, we hope our CBD products can help create a sense of calmness and wellbeing after a chaotic and unsettling year.”

Also Organics’ CBD Starter Pack makes it easy for those new to CBD and veteran users alike to try and enjoy a few best-selling products from the brand at a highly discounted price. The bundle includes:

  • 1000 mg CBD Tincture: full-spectrum, whole-plant CBD tincture that delivers a calm sense of wellbeing. Specially formulated with organic MCT oil and phyto-rich hemp oil, one 33 mg dose helps relieves anxiety and stress, and promotes focus and healthy sleep cycles.
  • 500 mg Skin Balm: provides powerful therapeutic agents like organic beeswax, CBD oil and eucalyptus oil to quickly soothe and protect dry and sensitive skin. The unique formula delivers unparalleled absorption and zero toxins that is safe for lips, face, hands, and the whole body.
  • 10 mg CBD Gummies: mixed fruit CBD gummies are great for creating a calm sense of wellbeing, relieving anxiety and stress, and improving overall body function. are great for creating a calm sense of wellbeing, relieving anxiety and stress, and improving overall body function. A daily 10 mg organic hemp gummy infused with vitamins can help relieve the effects of ADD, ADHD & ASD.


Naturally occurring cannabinoids, like CBD and CBG (cannabigerol), work with the built-in endocannabinoid system (ECS) of humans to help regulate both central nervous and immune systems. The entire Also Organics portfolio, which includes tinctures, gummies, gel caps, balms, salves and lotions, is non-psychoactive and made with US-grown hemp and organic ingredients. Additionally, the products are vegan, kosher-certified, non-GMO and free of gluten, dyes, paraben and fragrances.

Also Organics is committed to educating its customers on the complex qualities and potential therapeutic benefits of the hemp plant by offering publicly available insights and helpful facts featured on its website and social media properties. More information and the Also Organics product line is available online and in select medical clinics, wellness boutiques and retailers.

ABOUT ALSO ORGANICS:

Based in Nashville, Tenn., Also Organics creates personal wellness products with the finest, full-spectrum, whole plant CBD (and CBG) – all made from 100% American grown organic hemp. Also Organics offers a wide range of products including tinctures, gummies, gel caps, balms, salves, lotions and more. The Also Organics team believes there’s always more – to see, experience, and discover. The Also Organics portfolio is designed to unlock one’s potential and find balance in an increasingly chaotic world. For more information about Also Organics, visit http://www.AlsoOrganics.com. Also Organics can be found on Facebook, Instagram, and Twitter.

Media Contact:

Tiny Mighty Communications

Share article on social media or email:



Plant-Grow Inc. Announces New Microbial Growth Product MBX™ for Cannabis Growers


Cannabis grows big with MBX microbes

MBX Leaf Sample

MBX is incredibly productive during the first two weeks of both grow and bloom phases, so your plants’ root zones get the full benefits of our specially selected microbes. Harness the power of MBX microbial supplement to increase yields of the highest quality buds significantly.

Plant-Grow Inc., the world’s technology leader in microbial biofertilizers, is proud to announce MBX™. This microbial additive addresses the root of cannabis grower’s quest to increase the highest quality buds’ yields. MBX is an ultra-concentrated, proprietary blend of beneficial bacteria proven to increase root mass and quad yield. MBX’s billions of microorganisms benefit plants by working symbiotically with them to create bigger, healthier, more expansive roots, leading to bigger plants that thrive. MBX works for soil-growers, but it also works for hydroponic growers.

MBX is patent-pending. Plant-Grow documents its innovations with the TrustyIP invention management solution. Our IP submissions are then perfected and patented by the lawyers at the Patent Law Office, PC.

Mary Kimani, Product Manager in Nairobi, Kenya, states: “I’m proud to be part of a team to launch MBX. We have successfully selected unique microbial profiles that help cannabis root growth and rejuvenate soil depleted of nutrients through in-depth research. Optimizing the microbial communities that live in, on, and around the plants substantially reduce the need for chemical fertilizers, herbicides, and pesticides. MBX is proven to work great and has increased quad yield dramatically for the cannabis growers. Extensive trials have demonstrated that the product results in large quad buds with excellent pungency, sharp flavor, and smooth, clean-smelling burn smoke. “

The Plant-Grower program rewards our users and evangelists who spread the word about the efficacy of MBX. Plant-Growers earn extra money in helping fellow growers gain increased yield/potency and profit and saving the earth at the same time!

For more information on the program, go to http://www.plant-grow.com.

Share article on social media or email:

Quantiphi Named a Leader in New Analyst Report on Computer Vision Consultancies


“We believe being recognized a leader in CV Consultancies by Forrester is a testament to Quantiphi’s commitment to help clients build smarter products, frictionless customer experiences, and highly automated processes through Custom AI solutions” – Asif Hasan, Co-founder

Quantiphi today announced that it has been named a leader in The Forrester New Wave™: Computer Vision Consultancies, Q4 2020. The report by Forrester evaluates Computer Vision Providers That Matter Most And How they stack up based on three categories: Current offering, Strategy, and Market presence.

The inaugural report from Forrester identifies top vendors that offer computer vision (CV) consulting services in the market and assesses the relative strengths and weaknesses of computer vision consulting services offered by the most significant vendors. Based on the independent analysis, Quantiphi was named a leader in this report with differentiated ratings in the criteria of Data, Model Development, Solutions & Accelerators, Vision, and Market approach.

“Quantiphi has tackled a wider and more difficult range of CV projects than any other vendor in this evaluation, including digital pathology, contract analysis, automated inspection, student proctoring, and social distancing monitoring. And it has more prebuilt CV and AI components and platforms than you can point a camera at” states the Forrester report, authored by Kjell Carllson, PhD. “.”Quantiphi is a go-to vendor for any real-world CV problem”

“The ability of machines to perform cognitive tasks through visual inference has opened up entirely new possibilities for enterprises across a variety of industries,” said Asif Hasan, Co-Founder, Quantiphi. “Over the last few years, Quantiphi has worked extensively to provide AI-based CV solutions in medical imaging, manufacturing quality assurance, video safety and surveillance, image search and retrieval, visual recommender systems, and a range of other use cases. We believe being recognized a leader in CV Consultancies by Forrester is a testament to Quantiphi’s commitment to help clients build smarter products, frictionless customer experiences, and highly automated processes through Custom AI solutions.”

According to the Forrester report:


  • Quantiphi tackles quantifiably more, and more challenging, CV use cases.
  • Quantiphi is a go-to vendor for any real-world CV problem.”
  • Quantiphi could extend its CV offerings even more with CV-related partnerships, especially when it comes to unconventional hardware and data.
  • Customers praised Quantiphi for its expertise and transparency, as well as over delivering at competitive prices.


About Quantiphi

Quantiphi is an award-winning applied AI and data science software and services company driven by the desire to solve transformational problems at the heart of business. Quantiphi solves the toughest and complex business problems by combining deep industry experience, disciplined cloud and data engineering practices, and cutting-edge artificial intelligence research to achieve quantifiable business impact at unprecedented speed. We are passionate about our customers and obsessed with problem-solving to make products smarter, customer experiences frictionless, processes autonomous and businesses safer by detecting risks, threats and anomalies.

For more on Quantiphi’s capabilities, visit http://www.quantiphi.com

Share article on social media or email:

A Roadmap to Meet 2022 Deadlines, Upcoming Webinar Hosted by Xtalks


Now more than ever, in vitro diagnostic (IVD) manufacturers will need to prepare for the upcoming changes to the clinical and regulatory landscape.

Between the COVID-19 pandemic and BREXIT negotiations, the rapidly approaching deadlines to comply with the new In Vitro Diagnostics Regulation (IVDR) may have a profound impact on market access to products and, ultimately, patient outcomes. Now more than ever, in vitro diagnostic (IVD) manufacturers will need to prepare for the upcoming changes to the clinical and regulatory landscape.

Understanding current guidance and adapted regulations is the first step to navigating transformations that the diagnostics and broader healthcare industries are undergoing.

Join this webinar to learn about today’s IVD regulatory landscape and discuss how manufacturers can develop strategies to ensure a successful transition to comply with the IVDR by the 2022 deadline.

Join Ashleigh Dawley, RAC, Manager, Regulatory Affairs, Regulatory, Reimbursement and Market Access from ICON plc, in a live webinar on Thursday, December 17, 2020 at 11am EST (4pm GMT/UK).

For more information, or to register for this event, visit The IVDR Journey: A Roadmap to Meet 2022 Deadlines.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

HealthLX 3.3 Helps Healthcare Payers & Software Vendors Cross the Interoperability Finish Line for CMS Compliance


Healthcare interoperability pioneer HealthLX (HLX) announced it has released version 3.3 of its core platform. HealthLX is a managed clinical data exchange solution that drives business agility and advantage for payers and software vendors by enabling healthcare interoperability. With deadlines under the CMS Interoperability and Patient Access Final Rule quickly approaching, HealthLX has seen a sharp increase in focus by health plans on compliance with the mandate. A primary advantage of the HealthLX platform, now version 3.3, is that it enables payers to cross the finish line on compliance without incurring unnecessary costs, spending the time to build their own custom solutions, or replacing legacy systems.

In addition to an enhanced security infrastructure for FHIR/CMS protocols, including OAuth 2.0 and SMART on FHIR, other features new in HealthLX 3.3 include:


  • An enhanced FHIR server that supports several Da Vinci Payer Data Exchange (PDex) use cases, including those required by new CMS rules. The HealthLX enhanced FHIR Server is designed to support Patient API, Provider Directory, and eventually Payer-to-Payer data exchange, all out of the box. HealthLX 3.3 also gives health plans drag-and-drop capability to configure a FHIR Server via the Workflow Editor. The enhanced FHIR Server is also available in HealthLX’s free FHIR Starter Pak (FSP) offering.
  • A series of Workflow editor enhancements, including CSV templates for USCDI resource types previously available only in FSP. Health plans can now rely on the HealthLX 3.3 platform to import CCD and 837 file formats and process them into FHIR resources.

“One of our guiding principles for development of the HealthLX platform has been to enable interoperability with legacy or custom systems,” said HealthLX COO Charlie Provenzano. “We’re delivering on that commitment with a HealthLX 3.3 feature that allows technical professionals to import heavily-customized action components directly into our platform through the Workflow Editor. This innovation takes clients another step forward with interoperability without significant investment of their time or dollars.”

“HealthLX has been making strides forward in healthcare interoperability for years now through our work with payers and software vendors, and as a founding and active member of the Da Vinci Project,” said Will Tesch, CEO of HealthLX. “That’s one of the reasons HealthLX was listed as a Vendor by Gartner in its Hype Cycle for U.S. Healthcare Payers, 2020 Report. It is exciting and rewarding for us to see interoperability gain widespread momentum as organizations prepare for compliance with CMS Final Rule mandates. We expect that momentum to ramp up quickly as the July 1, 2021 deadline draws near.”

About HealthLX

HealthLX™ (Healthcare Language Exchange) gives new healthcare software solutions instant access to comprehensive patient information and real-time analytics by linking legacy data, applications and processes with modern approaches to application integration. The HealthLX platform is built around a software integration engine that is specifically designed for the interoperability needs of the healthcare industry, bridging older legacy systems to newly acquired solutions. HealthLX simplifies the effort and cost of new solution integration by configuring application (HL7, X.12, HIPAA) connectors to meet unique client needs. Designed with enhanced levels of transaction monitoring and security, the integration platform ensures message integrity and delivery. HealthLX implementation services are provided through its parent company, TESCHGlobal, an experienced, healthcare-focused professional services firm specializing in enterprise integration and business intelligence. For more information, visit http://www.healthlx.com.

For media inquiries, please contact:

Jennifer Behnke

Director of Marketing, HealthLX

marketing@healthlx.com

Share article on social media or email:

Xtalks Announces Its Life Science Webinar Calendar for December 2020


News Image

Stay on top of current hot topics through free webinars presented by leading experts in pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!

Visit http://www.xtalks.com to see our upcoming webinars:

BIOMARKERS

December 1- A Biomarker Journey in Immuno-Oncology Utilizing Immunohistochemistry

CLINICAL TRIALS

December 1- Digital Technologies for Assessing Patient Functioning in Multiple Sclerosis Clinical Trials

December 2- Case Study: Transforming Clinical Data Management from Legacy Processes to a Modern EDC Approach

December 3- The Value of Early Site Selection in Type 2 Diabetes Trials

December 3- Engaging Diverse Patient Populations in Rare Genetic Disease Clinical Research

December 4- Developing a Digital Protocol for Dermatology Trials: A Step-by-Step Guide to Optimizing Research for Patients and Clinicians

December 7- Risk-Based Optimization or Forecasting? The Impact on Clinical Trial Supply Planning

December 8- Meeting the Needs of Rare Disease Patients in Clinical Trials During the COVID-19 Pandemic

December 10- Designing a Successful Imaging-Based Pediatrics Clinical Trial

December 10- Enabling Decentralization with Patient-Focused eClinical Solutions

December 14- Strategic Comparator Sourcing in China: Optimizing the Clinical Supply Chain

December 15- Direct-to-Patient: Implementing Models for Continuous Treatment During the Pandemic and Beyond

COMMERCIALIZATION AND HEOR

December 7- Using R Shiny to Create Interactive and Web-Based Health Economic Models: Challenges and Opportunities

DRUG DISCOVERY AND DEVELOPMENT

December 3- Better Connections with Patients Using Data from Digital Pills

December 7- Strategies to Optimize Your Drug-Drug Interaction Program

December 10- Helping NASH Study Sites to Succeed: Insights into Operational Best Practices

December 11- Stabilizing the Unstable: Sample Stabilization Approaches for Unstable Compounds in Biological Matrices

December 14- Single-Cell Genomics Applications in Oncology Therapeutic Development: Resolving the Complexity of Cancer Heterogeneity

December 15- Maximizing Biorepositories for Research & Drug Discovery

FOOD

December 1- Wellness in a Bottle Series: What Do Consumers Want? (They Told Us)

December 4- Making Cultivation Financially Profitable and Optimizing Farm Potential with ‘Smarter Sesame’

December 7- Blockchain for Business Partners: Three Examples of Technology and Channel Partners Innovating with IBM Blockchain

December 9- Food and Beverage Industry Outlook for 2021

December 16- 2020 Pandemic: Key Learnings for the Food and Beverage Supply Chain

HEALTHCARE

December 2- Test. Better. Enhanced NIPT Reporting for Patients with Positive Results

December 8- Muscle-Liver Crosstalk and Sarcopenia in Chronic Liver Disease: Novel Techniques and Clinical Evidence

December 9- Laboratory Analysis of the ePlex® Blood Culture Panels for Timelier Diagnosis of Gram-Negative and Gram-Positive Bacteremia

LABORATORY TECHNOLOGY

December 16- Imaging AI and Machine Learning – Beyond the Hype

December 17- NeXT Liquid Biopsy: A High-Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics

December 17- Revolutionizing Risk-Based Monitoring Through On-Study Analytics

MEDICAL DEVICES

December 11- Introduction to the 3DEXPERIENCE License to Cure and its Applicability in Audit-Ready Medical Device Development

December 11- Selecting the Fast Path in Diagnostics Manufacturing Without Sacrificing Performance

December 17- The IVDR Journey: A Roadmap to Meet 2022 Deadlines

PHARMACEUTICAL

December 2- How to Maximize Pharmaceutical Supply Chain Efficiency and Security From Manufacturer to Patient

December 8- How Aseptic Filling Can Make Up Lost Time in a Drug Development Program

December 10- Pharmacovigilance Audit Failures: What’s Still Going Wrong?

December 15- From Promise to Reality: MyoKardia and Medpace Talk Precision Medicine in Cardiovascular Disease

PHARMACEUTICAL REGULATION

December 2- Creating Efficiency with Metadata-Driven End-to-End Standards

December 14- Meeting Pharmacopeia Regulations & Controlling the Risk of Contamination in Pharmaceutical Waters

December 17- The RACE for Children Act: Early Global Impact and Ensuring Success with Pediatric Champions

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://www.xtalks.com.

Share article on social media or email:

SFC Fluidics, Inc. Receives FDA Breakthrough Device Designation


SFC’s highly accurate insulin pod with rapid dispense confirmation.

SFC’s highly accurate insulin pod with rapid dispense confirmation.

“This pod is truly a breakthrough in its safety, immediately detecting the common blockages to pump flow and preventing traumatic insulin overdosing. It also provides exceptional dose accuracy.” -Barry Ginsberg, MD, PhD, Consulting Medical Director for SFC

SFC Fluidics, Inc. (SFC) is pleased to announce that its interoperable insulin delivery pod (the PandaTM), in late-stage development, has been granted Breakthrough Device Designation (BDD) by the Food and Drug Administration (FDA). The interoperable insulin delivery pod is intended for the subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in persons requiring insulin. SFC’s pod and its indications for use met several criteria designated by the BDD Program, including the promise of providing more effective treatment and offering significant advantages over existing approved or cleared alternatives.

SFC’s advanced microfluidic pumping system (ePump®) is designed to provide accurate delivery of extremely small doses of insulin without the resolution limits inherent in other commercially-available delivery devices. SFC believes its technology will effectively eliminate 95% of over and under dispenses of insulin.

SFC’s proprietary Dispense Confirmation Sensor (DCS™) represents a differentiating technology that can detect flow or no flow conditions of insulin in real-time. The DCS will quickly signal a lack of dispense for any reason. Currently available insulin pumps struggle with occlusion detection, especially at low doses. Some insulin pump systems cannot identify an occlusion for 20 hours or more, a very dangerous condition for patients. The DCS technology can detect an occlusion in six minutes or less.

Improved accuracy, precision, and resolution of dosing along with real-time confirmation of insulin delivery will allow dosing schemes and alert/alarm settings to be customized by a physician for each patient.

Barry Ginsberg, MD, PhD, Consulting Medical Director for SFC Fluidics stated, “This pod is truly a breakthrough in its safety, immediately detecting the common blockages to pump flow and preventing traumatic insulin overdosing. It also provides exceptional dose accuracy. As we progress to the next level of integrated diabetes care, these features will allow improved therapy of diabetes, resulting in better blood glucose control and fewer diabetes complications.”

“SFC is honored to receive the Breakthrough Device Designation. Being recognized by the FDA as the developer of a potentially game-changing device demonstrates promise for the future of our company’s role in improving diabetes therapy,” added Anthony Cruz, CEO of SFC Fluidics.

This work was supported in part by funding from JDRF, the leading global organization funding type 1 diabetes research.

SFC would also like to acknowledge the National Institutes of Health, including the National Institute of Diabetes and Digestive and Kidney Diseases, for help in funding various aspects of product development. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About SFC Fluidics, Inc.    

SFC Fluidics, Inc. has a mission to advance healthcare and improve quality of life through our enabling microfluidic technologies. The company’s vision is to become a recognized global leader in drug delivery, with a focus on insulin, where our unique product lines improve lifestyle and affordability. SFC Fluidics® is a VIC Technology Venture Development™ portfolio company. For more information, please visit https://www.sfc-fluidics.com/ or follow us on Twitter: @sfcfluidics.

Share article on social media or email:

Acumed Launches the ASCent™ Program for Ambulatory Surgery Centers


News Image

Choice is at the heart of this program, giving surgeons clinical options with clear pricing transparency.

Acumed’s ASCent is a customizable program designed to provide Ambulatory Surgery Centers (ASCs) with enhanced clinical value and pricing transparency.

Featuring Acumed’s comprehensive portfolio of medical devices for simple to complex injuries for the outpatient setting, the program is designed to provide surgeons with numerous options to meet in situ challenges for optimal patient outcomes.

Every ASC’s needs are unique. ASCent provides flexible pricing and billing structures to meet case needs and assist ASCs in complying with payor requirements, including fixed-price models.

Customizable, Scalable, Flexible: We understand what matters to our ASC customers.

“ASCs demand flexible business models that accommodate surgeon specialty and preference, as well as procedural requirements,” said Jim Devine, Director of Ambulatory Surgery Centers at Acumed.

The ASCent program is designed to provide scalable and customized options addressing the unique needs of independent facilities, regional networks, and national contracts. The program includes fixed-price structures for more than 75 procedure types. Pricing is established prior to surgery, providing numerous benefits that will lower the total cost of care, and is sharable with patients and payors. The program also may aid in procedure collections, since implant costs are often variable, which prevents accurate price estimates.

Sharon Wolfington, Acumed’s President and CEO said, “This program features Acumed’s comprehensive extremity fixation portfolio of medical devices at fixed procedure prices. Choice is at the heart of this program, giving surgeons clinical options with clear pricing transparency.”

Acumed has the most complete selection of upper extremity fixation and specialty plates on the market.* Acumed’s portfolio includes our comprehensive surgical trays designed for maximum flexibility covering a broad range of case needs, along with our Essential sets that are cost effective and minimize storage requirements while covering the majority of cases. Our loaner bank maintains numerous sets that can be shipped within 24 hours’ notice for operating room (OR) days working at maximum capacity.

Procedure packs are a convenient fixed-price option; however, they generate medical waste due to additional packaging, one-time use instruments, and disposed unused implants. Acumed’s flexible surgical trays contribute to each organization’s sustainability efforts by eliminating the waste generated by procedure packs.

Our ASC consultants will build a program that matches each ASC’s specific needs. We will adapt each program to reduce costs, improve efficiency, and facilitate compliance with payor requirements.

Over the past 30 years, Acumed has worked with more than 3,600 ASCs. We have met the needs of independent ASCs as well as hospital affiliated ambulatory surgery centers. “Acumed has delivered millions in cost savings with our customized program, serving thousands of surgery centers and multiple payors over the last two years,” said Aaron Greer, Director of National Accounts at Acumed. The ASCent program will serve patients, surgeons, ASC administrators, and payors with a consistent cost-of-care approach.

For more information or to schedule a presentation with our ASC dedicated team, please email ASCent@Acumed.net, or call Jim Devine (704.604.8123).

About Acumed

Acumed is a global leader in developing innovative orthopaedic and medical solutions to improve patient care. Acumed has more than three decades of experience in the orthopaedic industry, with the mission of aiding the afflicted through the ingenuity of our minds, the labor of our hands, and the compassion of our hearts. Founded in 1988, Acumed is headquartered in Hillsboro, Oregon, with offices and a distribution network around the world. For more information, visit acumed.net.

*Data on file with Acumed

Share article on social media or email:

Sapphire Essentials Launches a Science-based CBD Product Line Designed Specifically For The Needs of Those 40 And Up


News Image

We cultivate a proprietary strain of hemp specifically bred for the most medicinally concentrated cannabinoid strains of medical cannabis—without causing a drug high. You enjoy the benefits without the worry.

Ohio-based Sapphire Essentials announced today the full launch of their unique CBD product line, designed specifically to meet the needs of active adults and seniors. Sapphire products are made in the USA and use a proprietary & organically-grown hemp plant which delivers a broad spectrum, phytocannabinoid-rich and 100% THC-free CBD complex.

Sapphire Essentials was founded by nationally recognized healthy aging expert Dr. Jim Collins. As a Gerontologist focused on wellness and health care for seniors and older Americans, his 30-year plus career has spanned everything from Geropsychiatry to home health regimens for active seniors.

“I have been passionate about helping older and aging Americans. Members of this community, often overlooked by both traditional and holistic medicine, struggles daily with numerous physical and emotional health conditions. But they should not have to,” said Collins. With a burgeoning marketplace full of hemp-based “cures,” Collins differentiates his line. “While many CBD supplements are created with industrial hemp, and produce lower amounts of CBD, their end crop doesn’t yield the best medicinal outcome. We cultivate a proprietary strain of hemp specifically bred for the most medicinally concentrated cannabinoid strains of medical cannabis—without causing a drug high. You enjoy the benefits without the worry.”

Sapphire Essentials stands by their quality and can prove the standards they set make a difference. That starts with the type of cannabis used to make their products. Grown in the United States, their hemp is fully licensed and registered with the Colorado State Department of Agriculture. It is Non-GMO, GMP compliant, eco-friendly, solvent-free, lab tested and grown without pesticides. But Dr. Collins goes even further, asking those interested to do their homework, research the possible benefits of CBD, and read results on Sapphire Essentials’ website from third party testing of his products.

Dr. Collins also enlisted the help of another powerful voice in medicine. Dr. Leonard Wisneski, MD, has extensive knowledge and interest in the benefits of CBD and therapeutic applications involving the endocannabinoid system. With thirty years in the clinical practice of endocrinology, Dr. Wisneski is a recognized leader globally in the field of integrative and whole person health. His role at Sapphire Essentials is as a medical and scientific advisor.

“From my work with NIH, fellowships, time as an adjunct professor, and work with patients, I can easily marry the thought processes and results of cutting-edge research with that of the traditional doctor-patient experience. So, I understand how doctors treat aging issues and where science can go to do even more. I am proud to partner with Sapphire Essentials to help the aging community explore the possibilities for living a better life,” said Dr. Wisneski.

Every Sapphire Essentials product is fully lab tested and certified. Certificates of testing and information can be found on our website at http://www.sapphire-essentials.com. We are proud to offer consumer and wholesale partnerships on the website as well.

About Sapphire Essentials

Sapphire Essentials believes that everyone should be able to afford CBD supplements for their health and wellness. Our goal is to maximize quality of life organically for as many people as possible. Sapphire Essentials was created by a Gerontologist, licensed social worker, and a leader in senior care and we understand that older adults struggle daily with a number of physical and emotional health conditions. And while federal regulations will not allow us to state that CBD may help with specific ailments, we encourage everyone to do their research and become more educated on the possible benefits of CBD. For more information about Sapphire Essentials or our team, please visit http://www.sapphire-essentials.com.

Share article on social media or email:

Slone Partners Places Kevin B. Johnson as Senior Vice President of Regulatory Affairs at Inozyme Pharma


News Image

“Dr. Johnson is an experienced industry leader with extensive knowledge of the current regulatory landscape, in the United States and around the world.” said Slone Partners CEO Leslie Loveless.

Slone Partners, a nationwide executive search firm for life science, biotechnology, and diagnostics companies, has announced the placement of Kevin B. Johnson, Ph.D., MBA, as Senior Vice President of Regulatory Affairs at Inozyme Pharma. In his new role, Johnson is responsible for leading Inozyme’s global regulatory strategy.

Johnson brings to Inozyme more than 25 years of experience in developing and implementing global regulatory and clinical development strategies for rare diseases across entire product development lifecycles from preclinical through clinical development and ultimately to product approval for a variety of drugs, biologics, combination products and cell/gene therapies. Most recently, he served as Senior Vice President, Head of Regulatory and Quality, at Magenta Therapeutics, where he led the company’s global strategy for a portfolio of biologics. He has also served in senior management positions at Imara, Vtesse (later acquired by Sucampo, which was later acquired by Mallinckrodt Pharmaceuticals), and GlaxoSmithKline.

“Dr. Johnson is an experienced industry leader with extensive knowledge of the current regulatory landscape, in the United States and around the world.” said Slone Partners CEO Leslie Loveless. “He will be a tremendously valuable addition to the Inozyme executive team at a time when the company is moving aggressively to develop and bring to market the most advanced set of therapeutic breakthroughs for patients living with rare diseases.”

“We are thrilled to have Kevin join the Inozyme leadership team during this period of steady execution and as we prepare to enter clinical development,” said Axel Bolte, MSc, MBA, Co-founder, President and Chief Executive Officer of Inozyme Pharma. “Kevin is a talented regulatory affairs executive with deep experience in rare diseases and I look forward to Kevin’s contributions in helping Inozyme meet the needs of underserved patient communities.”

Johnson holds a Ph.D. in Neurobiology from the University of North Carolina School of Medicine, an MBA from the Kenan-Flagler School of Business at the University of North Carolina, and a B.S. in Chemistry from the University of South Florida. He also holds a Regulatory Affairs Certification (RAC) credential from the Regulatory Affairs Professional Society.

ABOUT SLONE PARTNERS

Slone Partners delivers the leaders who build amazing and diverse life sciences organizations – People Are Our Science®. Founded in 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established biotech, diagnostics, research tools, healthcare, precision medicine, CRO, and laboratory services companies. With coast-to-coast presence in the most active healthcare industry hubs of Boston, San Francisco, New York, Los Angeles, San Diego, Austin, Research Triangle Park NC, and Washington DC, Slone Partners uniquely and precisely provides an array of executive search and advisory services, including diversity, equity, and inclusion strategy, to innovative life sciences companies. To learn more about Slone Partners’ value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.

ABOUT INOZYME PHARMA

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. For more information, please visit http://www.inozyme.com.

Share article on social media or email: